KaloBios Pharma


Needham Comments On KaloBios Following Phase 2 KB001-A Trial Results In Cystic Fibrosis

In a research report sent to investors today, Needham analyst Alan Carr reiterated a Hold rating on KaloBios Pharmaceuticals (NASDAQ:KBIO), as the company yesterday …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts